The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the National Institute for Health and Care Excellence (NICE) has recommended Darzalex – also known as daratumumab – in combination with lenalidomide and dexamethasone.
The therapy concerns previously untreated multiple myeloma (MM) patients and will be available for routine use among adults across the NHS in England and Wales.
Recommendation criteria also involves patients who are newly diagnosed MM and for whom an autologous stem cell transplant (ASCT) is unsuitable…
